BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

被引：1

作者：

Reig Torras, O. ^{[1
]}

Crouzet, L. ^{[2
]}

Necchi, A. ^{[3
,4
]}

Baldini, C. ^{[5
]}

Lostes Bardaji, M. J. ^{[6
,7
]}

Doger de Speville, B. ^{[8
]}

Italiano, A. ^{[9
,10
]}

Verlingue, L. ^{[11
]}

Boni, V. ^{[12
]}

Carter, L. ^{[13
,14
]}

Duran, I. ^{[15
]}

Garmezy, B. ^{[16
]}

Galsky, M. D. ^{[17
]}

Falchook, G. S. ^{[18
]}

DeMars, L. ^{[19
]}

Josephs, K. ^{[20
]}

Xu, C. ^{[21
]}

Bader, J. ^{[22
]}

Fontana, E. ^{[23
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] Ctr Eugene Marquis, UNICANCER, Rennes, France

[3] Univ Vita Salute San Raffaele, Dept Med Oncol, Milan, Italy

[4] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[5] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

[6] Vall DHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Oncol Dept, Barcelona, Spain

[8] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Start Madrid Phase Unit 1, Madrid, Spain

[9] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France

[10] Univ Bordeaux, Bordeaux, France

[11] Ctr Leon Berard, Phase Clin Unit 1, Lyon, France

[12] NEXT Madrid, Univers Hosp Quiron Salud Madrid, Madrid, Spain

[13] Univ Manchester, Med Oncol, Manchester, Lancs, England

[14] Christie NHS Fdn Trust, Manchester, Lancs, England

[15] Hosp Univ Marques de Valdecilla IDIVAL, Dept Despacho 271, Santander, Spain

[16] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[17] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[18] HealthONE, Sarah Cannon Res Inst, Med Oncol, Denver, CO USA

[19] Bicycle Therapeut, Clin Dev, Cambridge, MA USA

[20] Bicycle Therapeut, Clin Sci, Cambridge, MA USA

[21] Bicycle Therapeut, Biostat, Cambridge, MA USA

[22] Bicycle Therapeut, Quantitat Pharmacol, Cambridge, MA USA

[23] Sarah Cannon Res Inst UK, Drug Dev, London, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.718

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

652P

引用

页码：S515 / S516

页数：2

共 50 条

[41] Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
Fiala, Ondrej
Buti, Sebastiano
Fujita, Kazutoshi
de Liano, Alfonso Gomez
Fukuokaya, Wataru
Kimura, Takahiro
Yanagisawa, Takafumi
Giannatempo, Patrizia
Angel, Martin
Mennitto, Alessia
Molina-Cerrillo, Javier
Bourlon, Maria T.
Soares, Andrey
Takeshita, Hideki
Calabro, Fabio
Ortega, Cinzia
Kucharz, Jakub
Milella, Michele
Seront, Emmanuel
Park, Se Hoon
Tural, Deniz
Benedetti, Giovanni
Urun, Yuksel
Battelli, Nicola
Melichar, Bohuslav
Poprach, Alexandr
Buchler, Tomas
Kopecky, Jindrich
Conteduca, Vincenza
Monteiro, Fernando Sabino Marques
Massari, Francesco
Gupta, Shilpa
Santoni, Matteo
CLINICAL & EXPERIMENTAL METASTASIS, 2025, 42 (02)
[42] Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Fiala, Ondrej
Massari, Francesco
Basso, Umberto
Giannatempo, Patrizia
Grande, Enrique
Buti, Sebastiano
Myint, Zin W.
De Giorgi, Ugo
Pichler, Renate
Grillone, Francesco
Urun, Yuksel
Calabro, Fabio
Bourlon, Maria T.
Galli, Luca
Kanesvaran, Ravindran
Roviello, Giandomenico
Kucharz, Jakub
Rizzo, Mimma
Park, Se Hoon
Cerbone, Linda
Seront, Emmanuel
Messina, Carlo
Molina-Cerrillo, Javier
Santini, Daniele
Yano, Akihiro
Incorvaia, Lorena
Catalano, Martina
Pinto, Alvaro
Formisano, Luigi
Soares, Andrey
Facchini, Gaetano
Fornarini, Giuseppe
Poprach, Alexandr
Rebuzzi, Sara Elena
Nasso, Cecilia
Spinelli, Gian Paolo
Angel, Martin
Stellato, Marco
Tural, Deniz
Aurilio, Gaetano
Epstein, Ilana
Carrozza, Francesco
Monteiro, Fernando Sabino Marques
Benedetti, Giovanni
Buchler, Tomas
Ortega, Cinzia
Zakopoulou, Roubini
Battelli, Nicola
Porta, Camillo
Bellmunt, Joaquin
TARGETED ONCOLOGY, 2024, 19 (06) : 905 - 915
[43] EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
O'Donnell, P.
Galsky, M. D.
Rosenberg, J. E.
Petrylak, D. P.
Balar, A. V.
McGregor, B. A.
Heath, E.
Yu, E. Y.
Quinn, D. I.
Hahn, N. M.
Campbell, M.
Liang, S-Y.
Steinberg, J.
Loriot, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S579 - S580
[44] The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
McGregor, B. A.
Sonpavde, G. P.
Kwak, L.
Gao, X.
Mantia, C.
Wei, X. X.
Berchuck, J. E.
Ravi, P.
Michaelson, M. D.
Choueiri, T. K.
Bellmunt, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1199 - S1200
[45] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
Jain, Rohit K.
Kim, Youngchul
Rembisz, Jennifer
Piekarz, Richard
Synold, Timothy W.
Zhang, Jingsong
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[46] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
Jain, Rohit K.
Heiligh, Jazlyn
Kim, Youngchul
Piekarz, Richard
Pelosof, Lorraine Cheryl
Yang, Yuanquan
D'souza, Anishka
Wong, Risa Liang
Graham, Laura
Gupta, Sumati
Park, Anna
Synold, Timothy W.
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 625 - 625
[47] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
Bedke, Jens
Van Der Heijden, Michiel Simon
Powles, Thomas
Valderrama, Begona Perez
Kikuchi, Eiji
Iyer, Gopa
Vulsteke, Christof
Swami, Umang
Castellano, Daniel
Sarwar, Naveed
Drakaki, Alexandra
Hoffman-Censits, Jean H.
Arafat, Waddah
Andabekov, Timur
Li, Jian-Ri
Lu, Yi-Tsung
Yu, Xuesong
Shetty, Aditya
Moreno, Blanca Homet
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Rosenberg, Jonathan
Sridhar, Srikala S.
Zhang, Jingsong
Smith, David
Ruether, Dean
Flaig, Thomas W.
Baranda, Joaquina
Lang, Joshua
Plimack, Elizabeth R.
Sangha, Randeep
Heath, Elisabeth I.
Merchan, Jamie
Quinn, David I.
Srinivas, Sandy
Milowsky, Matthew
Wu, Chunzhang
Gartner, Elaina M.
Zuo, Peiying
Melhem-Bertrandt, Amal
Petrylak, Daniel P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (10) : 1041 - +
[49] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
Van Der Heijden, Michiel Simon
Gupta, Shilpa
Bedke, Jens
Valderrama, Begona Perez
Kikuchi, Eiji
Iyer, Gopa
Loriot, Yohann
Dawson, Nancy Ann
Hoffman-Censits, Jean H.
Mar, Nataliya
Sridhar, Srikala S.
Maroto-Rey, Pablo
Shin, Sang Joon
Yu, Evan Y.
Duran, Ignacio
Birrenkott, Matthew
Yu, Xuesong
Shetty, Aditya
Bavle, Abhishek Amar
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Rosenberg, J. E.
Flaig, T. W.
Friedlander, T. W.
Milowsky, M. I.
Srinivas, S.
Petrylak, D. P.
Merchan, J. R.
Bilen, M. A.
Carret, A. -S.
Yuan, N.
Sasse, C.
Hoimes, C. J.
SWISS MEDICAL WEEKLY, 2020, : 26S - 27S

← 1 2 3 4 5 →